Posted on

Psychedelic music studio changes your attachment style: issue 22

Here’s what’s in store for you in today’s issue:

🍄 Psychedelic music studio receives $4.5M in funding

🍄 How your attachment style affects your trip

🍄 First-ever study with direct psilocin

🍄 A new helmet to understand the brain

🍄 And more.

Be sure to check out last week’s Daily Mushroom podcast:

The DMT Cure for Chronic Pain and PTSD

Kieran, a retired black ops vet who magically cured his neck pain with a wild DMT trip. Kieran talks about being in a constant stress state while serving and how psychedelics help him cope with ongoing PTSD.

Therapeutic banner

First-ever study with direct psilocin

When psilocybin is consumed, it’s metabolized into psilocin, which is the compound that produces most (or all) of the psychedelic effects.

Will the experience change if psilocin is administered directly?

Filament Health (FH) just received FDA-approval for a first-of-its kind study that will reveal the answer.

The phase I trial at the University of California San Francisco will compare the effects of psilocybin and psilocin in 20 healthy patients. Psilocybin will be administered orally, whereas psilocin will be administered both orally and sublingually, meaning it will be absorbed through tissues under the tongue.

Researchers predict that direct psilocin could result in faster onset times, greater consistency and bioavailability — with fewer side effects.

A faster treatment for depressed moms

Existing treatments for post-partum depression take up to 8 weeks and often separate the mother from her baby for long periods of time, creating even more stress.

Field Trip Health (FTRP) is developing a proprietary psychedelic to change this.

The formulation, FT-104, could be administered in just one day and lasts 2-3 hours shorter than pure psilocybin. The compound leaves the mother’s system in just 24 hours, allowing her to safely breastfeed again.

FT-104 is currently in preclinical evaluation with phase I trials expected to begin in Q1 of next year.

atai accelerates schizophrenia research after promising findings

atai Life Sciences (ATAI) developed a new compound that could help treat cognitive impairment associated with schizophrenia.

The compound, RL-007, was tested on a cohort of 8 schizophrenic patients while continuing with their antipsychotic treatments. Using brain mapping and other biomarkers, researchers found that formulation improved cognition by activating receptors linked to learning and memory. 

The findings were so promising that atai decided to spend additional resources to accelerate the compound into a Phase 2a trial, which should be completed by the end of the year.

Ending the PTSD crisis

The lack of effective PTSD treatments is “a crisis,” according to the PTSD Psychopharmacology Working Group. About one in 20 people in the UK suffer from PTSD, and current treatment options are ineffective for 40% of patients.

COMPASS Pathways (CMPS) is launching a phase II trial to see if its psilocybin therapy model for treatment-resistant depression can bring relief to patients with PTSD.

The trial will assess 20 patients who experienced trauma as adults. They will be given a single dose of the psilocybin formulation followed by 12 weeks of therapy protocols.

Researchers will measure the safety of the drug as well as improvements in PTSD symptoms, functionality, and quality of life.

inspirational banner

Psychedelic music studio receives $4.5M in funding

When patients have a positive response to music during psychedelic therapy, they’re more likely to have a mystical experience which can lead to a more effective treatment.

That’s why neuroscientist Dr. Mendel Kaelen co-founded Wavepaths – a music studio that uses AI to create customized music—on the fly—in response to a patient’s emotional state!

The implications of Wavepaths go far beyond psychedelic therapy: hospitals, birth clinics, hospice centers, and schools are showing interest in the technology. It is already being used in 30+ countries and over 5,000 practitioners await its public release.

How your attachment style affects your trip

If you’ve ever struggled with attachment anxiety in your relationships, there’s promising evidence that psilocybin could be an effective treatment:

After undergoing individual therapy, group therapy, and a single psilocybin session, a group of 18 male AIDS survivors showed significantly reduced scores for attachment anxiety – an attachment style characterized by clinginess, fear of abandonment, and difficulty trusting others.

There were no significant changes in attachment avoidance, which is characterized by repressing emotions and discomfort with close relationships.

However, high attachment anxiety scores were associated with a greater chance of mystical experiences, whereas high attachment avoidance scores were linked to grief, fear, physical distress, and paranoia during the trip.

What better way to feel more secure in your relationships than through a trip? 🤩

Old Town Road to success

Lil Nas X was honoured as a visionary at the Wall Street Journal’s Innovator Awards after releasing his latest album, ‘Montero.’ Were magic mushrooms the secret behind his success?

The artist says that his first-ever mushroom trip was a pivotal moment while recording the album. The experience helped him reflect on himself and break free from feelings of self-consciousness.

“I was able to open up a lot. I was able to write actual stories about my life and put it into my music. I actually did that for the first time,” Nas explained.

business banner

A new helmet to understand the brain

The LA-based company Kernel developed a brain-imaging helmet that can track what actually happens in the brain during a psychedelic trip.

The device, Kernel Flow, was just approved by the FDA to be used in a ketamine trial sponsored by Cybin (CYBN).

Researchers will use the helmet to measure the neurological activity of 15 patients during a ketamine therapy session compared to baseline activity.

Kernel Flow is much less expensive than other brain-imaging tools and allows the patients to move freely during the session.

Trip at home with a psychedelic patch

PharmaTher (PHRM) and Revive Therapeutics (RVV) are entering into a research agreement to develop psychedelic patches that could be used at home!

The biodegradable patches will use microneedles to deliver both micro and macrodoses of psilocybin, ketamine, MDMA, LSD, DMT, ibogaine, and mescaline.

PharmaTher is currently studying the effects of the psilocybin microdose patch, with results expected by the end of this month.

The companies aim to create a delivery method that’s safe and convenient enough for patients to administer on their own, without supervision.

PharmaTher (PHRM) and Revive Therapeutics (RVV) are entering into a research agreement to develop psychedelic patches that could be used at home!

The biodegradable patches will use microneedles to deliver both micro and macrodoses of psilocybin, ketamine, MDMA, LSD, DMT, ibogaine, and mescaline.

PharmaTher is currently studying the effects of the psilocybin microdose patch, with results expected by the end of this month.

The companies aim to create a delivery method that’s safe and convenient enough for patients to administer on their own, without supervision.

Creating a myriad of drugs with AI

Using an AI drug discovery program, Mydecine (MYCO) successfully added a novel psilocin analogue with improved delivery and stability to its pipeline.

The AI technology synthesizes billions of drug candidates and filters them based on psychedelic-related targets such as how they bind to receptors.

Mydecine also filed a patent for nanoemulsion technology. Nanoemulsion can:

  • help the company develop compounds inspired by traditional plant medicines such as reishi and cordyceps mushrooms
  • improve control in delivery, which is critical in microdosing and customizing dosages
  • advance development of over-the-counter consumer products
legal banner

Detroit decriminalizes psychedelics!

With a 61% to 39% win, Detroit became the fourth city in Michigan to widely decriminalize possession and therapeutic use of psychedelics.

Over 80% voted to establish a reparations committee that will address historical discrimination against Black communities through housing and economic development programs.

Industry Quick Hits

Oct 29 – Oppenheimer initiates COMPASS Pathways (CMPS) with a buy rating and $50 price target Read more…

Oct 29 – Braxia Scientific (BRAX) Announces Voting Results from the Annual General Meeting of Shareholders Read more…

Nov 1 – Blackhawk Growth’s (BLR) MindBio Therapeutics Looks to Expand Microdosing Clinical Trials Read more…

Nov 1 – Algernon Pharmaceuticals (AGN) reports positive pre-clinical data on DMT candidate to treat stroke Read more…

Nov 1 – Small Pharma (DMT) reports second quarter highlights Read more…

Nov 2 – Braxia Scientific (BRAX) Graduates First Cohort of Medical Professionals From Psilocybin-Assisted Therapy Training Program Read more… 

Nov 2 – U.S. FDA Approves Nova Mentis (NOVA) Orphan Drug Application Read more…

Nov 2 – Tryp Therapeutics (TRYP) Submits IND Application for Phase 2a Clinical Trial in Fibromyalgia Read more…

Nov 3 – Amanita Muscaria Mushroom Successfully Added to the Natural Health Products Ingredients Database (NHPID) of Canada Read more…

Nov 4 – Awakn Life Sciences (AWKN) Announces The Findings From Phase II A/B Study Are To Be Published In American Journal Of Psychiatry Read more…

Nov 5 – Novamind (NM) Reports FY2021 Financial Results and Operating Highlights Read more…

Nov 5 – NeonMind (NEON) Biosciences Named As A Top Industry Innovator In Inaugural Issue Of Psychedelia Magazine Read more…

Video of the Week

Trippy Mushroom-Themed Resort

Playlist of the Week

60s - 70s stoner rock
Posted on

First-ever study with direct psilocin

Filament Health Announces FDA Authorization of Clinical Trial with First-ever Direct Psilocin Administration and First-ever Psychedelic Botanical Drug Candidates

When psilocybin is consumed, it’s metabolized into psilocin, which is the compound that produces most or all of the psychedelic effects. Will the experience change if is psilocin is administered directly?

Filament Health (FH) just received FDA-approval for a first-of-its kind study that will reveal the answer.

The phase I trial at the University of California San Francisco will compare the effects psilocybin and psilocin in 20 healthy patients. Psilocybin will be administered orally, whereas psilocin will be administered both orally and sublingually, meaning it will be absorbed through tissues under the tongue.

Researchers predict that direct psilocin could result in faster onset times, greater consistency and bioavailability, and fewer side effects.

PDF of article

Posted on

Filament Health Announces FDA Authorization of Clinical Trial with First-ever Direct Psilocin Administration and First-ever Psychedelic Botanical Drug Candidates

Filament Health Announces FDA Authorization of Clinical Trial with First-ever Direct Psilocin Administration and First-ever Psychedelic Botanical Drug Candidates

The Phase 1 Trial is Taking Place at the Translational Psychedelic Research Program at the University of California San Francisco

Vancouver, British Columbia, November 2, 2021  – Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) (“Filament” or the “Company”), an exclusively-natural psychedelic drug discovery company, announces FDA authorization to initiate the first clinical trial using naturally-sourced psychedelic substances. In addition, this approval is the first for the direct administration of psilocin rather than its prodrug psilocybin and will administer Filament’s three proprietary botanical drug candidates. The phase 1 trial is led by the Translational Psychedelic Research Program (TrPR) at the University of California San Francisco (UCSF).

“We are excited to announce this milestone as validation of our ability to cultivate variable psychedelic biomass and transform it into pharmaceutical-grade drug candidates,” said Chief Executive Officer, Benjamin Lightburn. “Our innovative technology has allowed us to create IP-protected botanical drug candidates of oral psilocin, sublingual psilocin, and oral psilocybin, and to enter them into an FDA-approved natural psychedelic clinical trial. Our candidates enjoy significant IP protection, unlike most other psychedelics currently under clinical investigation.”

The phase 1 trial has been designed to include 20 healthy subjects and will examine the effects of Filament’s three proprietary botanical drug candidates: PEX010 (oral psilocybin), PEX020 (oral psilocin), and PEX030 (sublingual psilocin). As a result of the need for psilocybin to convert into psilocin before becoming active in the human body, the direct administration of psilocin may yield several therapeutic benefits such as faster onset time, greater consistency, increased bioavailability, and lessened side effects. These potential attributes are being studied in the authorized trial. In addition, psilocin is an ideal candidate for sublingual delivery because of the bypassing of the gut, where the conversion to psilocybin is thought to primarily occur. To date, synthetic manufacturers have been unable to produce a stable formulation of psilocin and enter it into a clinical trial.

“My team and I are very excited to begin dosing Filament’s drug candidates in our clinic,” said Dr. Josh Woolley, MD/Ph.D., Director of TrPR and the study’s Principal Investigator. “The oral and sublingual administration presents an opportunity to learn about psilocin’s effects compared to psilocybin and perhaps set a new standard for psychedelic assisted therapy.”

Further information about the history and benefits of psilocin can be found at https://filament.health/psilocybin-vs-psilocin.

 

ABOUT FILAMENT HEALTH

Filament Health is an exclusively-natural psychedelic drug discovery and extraction technology company. Its mission is to see safe, approved, natural psychedelics in the hands of everyone who needs them as soon as possible. Filament believes measurable and efficacious medicines will be a catalyst to addressing many of the world’s mental health problems and that natural psychedelics provide an optimal option for widespread adoption of these substances. Filament engages in natural extraction technology commercialization, utilizing its intellectual property portfolio, and its subsidiary Psilo Scientific’s in-house GMP facility, and Health Canada Dealer’s License for all natural psychedelics. Filament is headquartered in Vancouver, British Columbia and trades on the OTCQB Venture Market (OTCQB:FLHLF), Canada’s NEO Exchange (NEO:FH), and the Frankfurt Stock Exchange (FSE:7QS).

Learn more at www.filament.health and on Twitter, Instagram and LinkedIn.

 

MEDIA RELATIONS

Anna Cordon, Director of Communications
778.245.9067
anna@filament.health

 

INVESTOR RELATIONS CONTACT

KCSA Strategic Communications
Tim Regan/Adam Holdsworth
347.487.6788
FilamentIR@KCSA.com

 

FORWARD LOOKING INFORMATION

Certain statements and information contained herein may constitute “forward-looking statements” and “forward-looking information,” respectively, under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as, “expect”, “anticipate”, “continue”, “estimate”, “may”, “will”, “should”, “believe”, “intends”, “forecast”, “plans”, “guidance” and similar expressions are intended to identify forward-looking statements or information. Forward-looking statements herein include, but are not limited to, statements regarding the benefits of psilocin as compared to psilocybin. The forward-looking statements are not historical facts, but reflect the current expectations of management of Filament regarding future results or events and are based on information currently available to them. Certain material factors and assumptions were applied in providing these forward-looking statements. Forward-looking statements regarding the Company are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of Filament to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including results of the clinical trial. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Filament will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.

Posted on

KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing

KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing

NEW YORK, Oct. 18, 2021 /PRNewswire/ — Virtual Investor Conferences in partnership with KCSA Strategic Communications today announced the presentations from the KCSA Psychedelics Virtual Investor Conference are now available for on-demand viewing.

REGISTER OR LOGIN NOW AT: https://bit.ly/3acCV7Y

The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download shareholder materials from the company’s “virtual trade booth”.

Presentations

PresentationTicker(s)
Fireside Chat – Amy Emerson, CEO of MAPS Public Benefit Corporation
“Investing in Psychedelics and CNS Treatments”       Lindsay Hoover, Partner, JLS Fund       Dan Ahrens, PM of the Psychedelics ETF (NYSEArca: PSIL), AdvisorShares Investments       Tim Regan, SVP, KCSA Strategic Communications
Small Pharma Inc.(Pink: DMTTF | TSX-V: DMT)
Awakn Life Sciences Corp.(OTCQB: AWKNF | NEO: AWKN)
HMNC Brain Health(Private Company)
Enveric Biosciences(NASDAQ: ENVB)
Mind Cure Health Inc.(OTCQX: MCURF | CSE: MCUR)
Field Trip Health Ltd.(NASDAQ: FTRB | TSX: FTRP)
Novamind Inc.(OTCQB: NVMDF | CSE: NM)
BetterLife Pharma Inc.(OTCQB: BETRF | CSE: BETR)
MYND Life Sciences Inc.(Pink: MYNDF | CSE: MYND)
FSD Pharma Inc.(NASDAQ: HUGE | CSE: HUGE)
Mindset Pharma Inc.(OTCQB: MSSTF | CSE: MSET)
PsyBio Therapeutics Corp.(OTCQB: PSYBF | TSX-V: PSYB)
Psyched Wellness Ltd.(OTCQB: PSYCF | CSE: PSYC)
Bright Minds Biosciences Inc.(OTCQB: BMBIF | CSE: DRUG)
Cybin Inc.(NYSE American: CYBN | NEO: CYBN)
Mydecine Innovations Group(Pink: MYCOF | NEO: MYCO)
NeonMind Biosciences Inc.(OTCQB: NMDBF | CSE: NEON)
Numinus Wellness Inc.(TSX-V: NUMI)
Tryp Therapeutics Inc.(OTCQB: TRYPF | CSE: TRYP)
Wesana Health Holdings Inc.(OTCQB: WSNAF | CSE: WESA)
Filament Health Corp.(OTCQB: FLHLF | NEO: FH)

To facilitate investor relations scheduling, please contact KCSA Strategic Communications a conference@kcsa.com.

About Virtual Investor ConferencesSM
Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly-traded companies to meet and present directly with investors.

A real-time solution for investor engagement, Virtual Investor Conferences is part of OTC Market Group’s suite of investor relations services specifically designed for more efficient Investor Access.  Replicating the look and feel of on-site investor conferences, Virtual Investor Conferences combine leading-edge conferencing and investor communications capabilities with a comprehensive global investor audience network.

To learn more about VIC and view a complete calendar of events, please visit www.virtualinvestorconferences.com.

About KCSA Strategic Communications
KCSA is a fully integrated communications agency specializing in public relations, investor relations and social media, with expertise in financial and professional services, technology, healthcare, digital media and cannabis. Since 1969, the firm has demonstrated strategic thinking and program execution that drives results for its clients in the ever-changing communications and digital landscape. The firm’s clients are its best references. For more information, please visit www.kcsa.com.

SOURCE VirtualInvestorConferences.com

Posted on

KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing

KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing

Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations

NEW YORK, Oct. 18, 2021 /CNW/ – Virtual Investor Conferences in partnership with KCSA Strategic Communications today announced the presentations from the KCSA Psychedelics Virtual Investor Conference are now available for on-demand viewing.

REGISTER OR LOGIN NOW AT: https://bit.ly/3acCV7Y

The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download shareholder materials from the company’s “virtual trade booth”.

Presentations

Presentation

Ticker(s)

Fireside Chat – Amy Emerson, CEO of MAPS Public Benefit Corporation

“Investing in Psychedelics and CNS Treatments”

       Lindsay Hoover, Partner, JLS Fund

       Dan Ahrens, PM of the Psychedelics ETF (NYSEArca: PSIL), AdvisorShares Investments

       Tim Regan, SVP, KCSA Strategic Communications

Small Pharma Inc.

(Pink: DMTTF | TSX-V: DMT)

Awakn Life Sciences Corp.

(OTCQB: AWKNF | NEO: AWKN)

HMNC Brain Health

(Private Company)

Enveric Biosciences

(NASDAQ: ENVB)

Mind Cure Health Inc.

(OTCQX: MCURF | CSE: MCUR)

Field Trip Health Ltd.

(NASDAQ: FTRB |TSX: FTRP)

Novamind Inc.

(OTCQB: NVMDF | CSE: NM)


BetterLife Pharma Inc.

(OTCQB: BETRF | CSE: BETR)

MYND Life Sciences Inc.

(Pink: MYNDF | CSE: MYND)

FSD Pharma Inc.

(NASDAQ: HUGE | CSE: HUGE)

Mindset Pharma Inc.

(OTCQB: MSSTF | CSE: MSET)

PsyBio Therapeutics Corp.

(OTCQB: PSYBF | TSX-V: PSYB)

Psyched Wellness Ltd.

(OTCQB: PSYCF | CSE: PSYC)

Bright Minds Biosciences Inc.

(OTCQB: BMBIF | CSE: DRUG)

Cybin Inc.

(NYSE American: CYBN | NEO: CYBN)


Mydecine Innovations Group

(Pink: MYCOF | NEO: MYCO)

NeonMind Biosciences Inc.

(OTCQB: NMDBF | CSE: NEON)

Numinus Wellness Inc.

(TSX-V: NUMI)

Tryp Therapeutics Inc.

(OTCQB: TRYPF | CSE: TRYP)

Wesana Health Holdings Inc.

(OTCQB: WSNAF | CSE: WESA)

Filament Health Corp.

(OTCQB: FLHLF | NEO: FH)

To facilitate investor relations scheduling, please contact KCSA Strategic Communications a conference@kcsa.com.

About Virtual Investor ConferencesSM
Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly-traded companies to meet and present directly with investors.

A real-time solution for investor engagement, Virtual Investor Conferences is part of OTC Market Group’s suite of investor relations services specifically designed for more efficient Investor Access.  Replicating the look and feel of on-site investor conferences, Virtual Investor Conferences combine leading-edge conferencing and investor communications capabilities with a comprehensive global investor audience network.

To learn more about VIC and view a complete calendar of events, please visit www.virtualinvestorconferences.com.

About KCSA Strategic Communications
KCSA is a fully integrated communications agency specializing in public relations, investor relations and social media, with expertise in financial and professional services, technology, healthcare, digital media and cannabis. Since 1969, the firm has demonstrated strategic thinking and program execution that drives results for its clients in the ever-changing communications and digital landscape. The firm’s clients are its best references. For more information, please visit www.kcsa.com.

SOURCE VirtualInvestorConferences.com

For further information: Media Contact: OTC Markets Group Inc., (212) 896-4428, media@otcmarkets.com; Investor Contacts: John M. Viglotti, SVP Corporate Services, Investor Access, OTC Markets Group, (212) 220-2221, johnv@otcmarkets.com; Tim Regan/Allison Soss, KCSA Strategic Communications,(212) 682-6300, conference@kcsa.com

Posted on

KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14th

KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14th

Psychedelic and CNS Company Executives share vision, answer questions live at VirtualInvestorConferences.com 

NEW YORK, Oct. 11, 2021 /CNW/ – Virtual Investor Conferences in partnership with KCSA Strategic Communications today announced the agenda for the upcoming KCSA Psychedelics Virtual Investor Conference. Individual investors, institutional investors, advisors, and analysts are invited to attend the two-day program beginning Wednesday, October 13, 2021, at 9:45 a.m. ET.

“The psychedelics industry is poised to provide much needed therapies to address the global mental health crisis. Some of the companies presenting over the next two days may be the next Pfizer, Roche or Sanofi,” commented Lewis Goldberg, Managing Partner at KCSA Strategic Communications.

REGISTER NOW AT: https://bit.ly/3acCV7Y

It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There are no fees to log-in, attend the live presentations or ask questions.

October 13th Agenda:  

Eastern
Time (ET)

Presentation

Ticker(s)

9:45 AM

KCSA Welcome Remarks

10:00 AM

Small Pharma Inc.

(Pink: DMTTF | TSX-V: DMT)

10:30 AM

Awakn Life Sciences Corp.

(OTCQB: AWKNF | NEO: AWKN)

11:00 AM

HMNC Brain Health

(Private Company)

11:30 AM

Enveric Biosciences

(NASDAQ: ENVB)

12:00 PM

Mind Cure Health Inc.

(OTCQX: MCURF | CSE: MCUR)

12:30 PM

Field Trip Health Ltd.

(NASDAQ: FTRB)

1:00 PM

Novamind Inc.

(OTCQB: NVMDF | CSE: NM)

1:30 PM


BetterLife Pharma Inc.

(OTCQB: BETRF | CSE: BETR)

2:00 PM

MYND Life Sciences Inc.

(Pink: MYNDF | CSE: MYND)

October 14th Agenda:

Eastern
Time (ET)

Presentation

Ticker(s)

9:55 AM

KCSA Opening Remarks

10:00 AM

Mindset Pharma Inc.

(OTCQB: MSSTF | CSE: MSET )

10:30 AM

PsyBio Therapeutics Corp.

(OTCQB: PSYBF | TSX-V: PSYB)

11:00 AM

Psyched Wellness Ltd.

(OTCQB: PSYCF | CSE: PSYC)

11:30 AM

Bright Minds Biosciences Inc.

(OTCQB: BMBIF | CSE: DRUG)

12:00 PM ET

Fireside Chat – Amy Emerson, CEO of MAPS Public Benefit Corporation

12:30 PM ET

Lunch Panel – Hosted by KCSA’s Tim Regan “Investing in Psychedelics and CNS Treatments”

1:00 PM

Cybin Inc.

(NYSE American: CYBN | NEO: CYBN)

1:30 PM


Mydecine Innovations Group

(Pink: MYCOF | NEO: MYCO)

2:00 PM

NeonMind Biosciences Inc.

(OTCQB: NMDBF | CSE: NEON)

2:30 PM

Numinus Wellness Inc.

(TSX-V: NUMI)

3:00 PM

Tryp Therapeutics Inc.

(OTCQB: TRYPF | CSE: TRYP)

3:30 PM

Wesana Health Holdings Inc.

(OTCQB: WSNAF | CSE: WESA)

4:00 PM

Filament Health Corp.

(Pink: FLHLF | NEO: FH)

To facilitate investor relations scheduling, please contact KCSA Strategic Communications a conference@kcsa.com.

About Virtual Investor ConferencesSM
Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly-traded companies to meet and present directly with investors.

A real-time solution for investor engagement, Virtual Investor Conferences is part of OTC Market Group’s suite of investor relations services specifically designed for more efficient Investor Access.  Replicating the look and feel of on-site investor conferences, Virtual Investor Conferences combine leading-edge conferencing and investor communications capabilities with a comprehensive global investor audience network.

To learn more about VIC and view a complete calendar of events, please visit www.virtualinvestorconferences.com.

About KCSA Strategic Communications
KCSA is a fully integrated communications agency specializing in public relations, investor relations and social media, with expertise in financial and professional services, technology, healthcare, digital media and cannabis. Since 1969, the firm has demonstrated strategic thinking and program execution that drives results for its clients in the ever-changing communications and digital landscape. The firm’s clients are its best references. For more information, please visit www.kcsa.com.

SOURCE VirtualInvestorConferences.com

For further information: Media Contact: OTC Markets Group Inc., (212) 896-4428, media@otcmarkets.com; Investor Contacts: John M. Viglotti, SVP Corporate Services, Investor Access, OTC Markets Group, (212) 220-2221, johnv@otcmarkets.com; Tim Regan/Allison Soss, KCSA Strategic Communications, (212) 682-6300, conference@kcsa.com

Posted on

Filament Health Announces Q2 2021 Financial Results

Developments include $7.8 million cash position, go public transaction and financing, FDA clinical trial progress, licensing expansion, and first patent issuance

Vancouver, British Columbia, August 16, 2021 – Filament Health Corp. NEO:FH. (“Filament” or the “Company”), a leading exclusively-natural psychedelic drug development company, today released its second quarter unaudited financial results and business highlights for the period ended June 30, 2021. Filament announced an active quarter punctuated by industry-leading developments, including the issuance of a patent for the extraction of natural psilocybin and the advancement of its proprietary natural psychedelic extracts through FDA clinical trials. A copy of the Company’s unaudited condensed interim consolidated financial statements, and management’s discussion and analysis for the three and six months ended June 30, 2021, can be found under the Company’s profile on SEDAR at www.sedar.com.

Second Quarter and Post Period Business Highlights

  • Completed go public transaction and pre-IPO financing round in advance of June 24th NEO Exchange listing. Use of proceeds includes clinical trials, research and development, intellectual property initiatives, and working capital.
  • Granted industry-first patent from the Canadian Intellectual Property Office related to the extraction and standardization of natural psilocybin and associated psychoactive compounds.
  • Patent filings portfolio expanded to over one dozen, covering extraction, standardization, purification, and delivery of APIs (Active Pharmaceutical Ingredients).
  • Received amendment to Health Canada Dealer’s License allowing for broad activities with all controlled natural psychedelic substances. Obtained IRB approval to conduct industry-first FDA clinical trial featuring a GMP-grade natural mushroom compound, in partnership with the Translational Psychedelic Research (TrPR) program at University of California, San Francisco (UCSF).
  • Completed three batches of proprietary mushroom extracts, including leading drug candidates PEX010, PEX020, and PEX030 for upcoming FDA clinical trials.

Second Quarter Financial Highlights

  • Well capitalized with cash and cash equivalents of $7.8 million as of June 30, 2021.
  • Closed on $5 million private placement.

Commentary and Outlook

“This has been a period of significant growth and development for Filament Health,” said Benjamin Lightburn, Chief Executive Officer. “We spent the past year focused on establishing fundamentals and building a scalable platform. Our rapid progress in these areas allowed us to list on a senior exchange, confident in our ability to drive shareholder value. Since listing, we have continued to innovate, with recent accomplishments in intellectual property, licensing, and drug development positioning Filament at the forefront of natural psychedelic research and manufacturing. We are committed to maintaining this pace of innovation in order to support the treatment of mental health conditions with safe, natural psychedelics as soon as possible.”

Leadership Announcement

Filament also announced that as of September 1, 2021, Tom Kineshanko will be transitioning to a new position as Founding Advisor from his role as President. He will maintain an active role in operational oversight, shareholder communications, and strategy. Mr. Kineshanko is one of the Company’s co-founders and has been paramount in developing its vision and strategy.

“Having founded Filament and seeing it achieve a public listing and advanced operating platform, it is the ideal time for me to transition to an advisory position,” said Mr. Kineshanko. “Filament is led by both an exceptional management team and committed Board of Directors and I look forward to contributing to Filament’s future strategic roadmap and operational focus.”

 

ABOUT FILAMENT HEALTH

Filament is an exclusively-natural psychedelic drug discovery and extraction technology company. Its mission is to see safe, approved, natural psychedelics in the hands of everyone who needs them as soon as possible. Filament believes measurable and efficacious medicines will be a catalyst to addressing many of the world’s mental health problems and that natural psychedelics provide an optimal option for widespread adoption of these substances. Filament engages in natural extraction technology commercialization, utilizing its intellectual property portfolio, in-house GMP facility, and Health Canada Dealer’s License for all natural psychedelics. Filament is headquartered in Vancouver, British Columbia and trades on Canada’s NEO Exchange (NEO:FH).

Learn more at www.filament.health and on Twitter, Instagram and LinkedIn.

 

MEDIA CONTACT

Anna Cordon, Director of Communications
778.245.9067
anna@filament.health

 

INVESTOR RELATIONS CONTACT

ir@filament.health

 

FORWARD LOOKING INFORMATION

Certain statements and information contained herein may constitute “forward-looking statements”and “forward-looking information,” respectively, under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as, “expect”, “anticipate”, “continue”, “estimate”, “may”, “will”, “should”, “believe”, “intends”, “forecast”, “plans”, “guidance” and similar expressions are intended to identify forward-looking statements or information. The forward-looking statements are not historical facts, but reflect the current expectations of management of Filament regarding future results or events and are based on information currently available to them. Certain material factors and assumptions were applied in providing these forward-looking statements. The forward-looking statements discussed in this press release may include, but are not limited to, information concerning Filament’s and TrPR’s ability to conduct clinical trials; the results of the partnership; the nature, timing, and possible success of Filament’s leading drug candidates and the impact and accessibility of psychedelic treatments. Forward-looking statements regarding the Company are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of Filament to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Filament will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.

Posted on

Going against the industry standard

Filament Health Is the First Public Company to be Issued a Patent for Extraction of Natural Psilocybin

Since natural psilocybin is typically expensive to extract, most companies create synthetic psilocybin, but not Filament Health (FH).

The Vancouver-based company developed an innovative technology that extracts and standardizes natural psilocybin to overcome crop-to-crop and flush-to-flush variability at a low cost. On Tuesday, Filament received a patent for the process, making it the first publicly traded company to receive a patent from the Canadian Intellectual Property Office for the extraction of natural psilocybin.

Posted on

Filament Health Is the First Public Company to be Issued a Patent for Extraction of Natural Psilocybin

Filament’s patent describes the extraction of stable, standardized doses of psychoactive compounds at its Health Canada-licensed, GMP-certified facility

Vancouver, British Columbia, August 3, 2021 – Filament Health Corp. NEO:FH. (“Filament” or the “Company”), a leading exclusively-natural psychedelic drug development company, today announced that it is the first public company to be issued a patent by the Canadian Intellectual Property Office for the extraction and standardization of natural psilocybin and associated psychoactive compounds. The patent describes essential technology for transforming variable psychedelic raw materials into pharmaceutical-grade standardized extracts.

This successful issuance validates Filament’s intellectual property strategy and sets the Company in good stead for allowances of pending patents covering additional elements of its proprietary technologies.

“We are proud to lead the industry with this first issued natural extraction patent. This approval represents important progress in the development of our intellectual property,” said Benjamin Lightburn, Chief Executive Officer. “At Filament Health, we know that nature is a valuable source of medicine, but that certain technologies are necessary to bring natural products up to a pharmaceutical grade—most importantly, through standardization.”

Filament has developed innovative technology to extract and standardize a stable dose of natural psilocybin in order to overcome crop-to-crop and flush-to-flush variability. Previous methods of natural extraction have experienced challenges relating to poor yields, stability, and repeatability. As a result, synthetic preparations of psilocybin have become the industry standard. Leveraging decades of natural extraction expertise, Filament has overcome these issues to produce a superior product at a lower cost.

“This achievement affirms Filament’s talent for innovation and demonstrates that we recognize the importance of protecting shareholder value,” said Taran Grey, Director of Intellectual Property (IP). “The concern that a third party could irreparably interfere with our operations by asserting IP against us is no longer the same threat as it is for others.”

The issuance of Filament’s patent comes soon after the Company was granted an amendment to its Health Canada Dealer’s License on July 28, 2021, which allows for broad operations with all controlled natural psychedelic substances.

 

ABOUT FILAMENT HEALTH

Filament is an exclusively-natural psychedelic drug discovery and extraction technology company. Its mission is to see safe, approved, natural psychedelics in the hands of everyone who needs them as soon as possible. Filament believes measurable and efficacious medicines will be a catalyst to addressing many of the world’s mental health problems and that natural psychedelics provide an optimal option for widespread adoption of these substances. Filament engages in natural extraction technology commercialization, utilizing its intellectual property portfolio, in-house GMP facility, and Health Canada Dealer’s License for all natural psychedelics. Filament is headquartered in Vancouver, British Columbia and trades on Canada’s NEO Exchange (NEO:FH).

Learn more at www.filament.health and on Twitter, Instagram and LinkedIn.

 

MEDIA CONTACT

Anna Cordon, Director of Communications
778.245.9067
anna@filament.health

 

INVESTOR RELATIONS CONTACT

ir@filament.health

 

FORWARD LOOKING INFORMATION

Certain statements and information contained herein may constitute “forward-looking statements”and “forward-looking information,” respectively, under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as, “expect”, “anticipate”, “continue”, “estimate”, “may”, “will”, “should”, “believe”, “intends”, “forecast”, “plans”, “guidance” and similar expressions are intended to identify forward-looking statements or information. The forward-looking statements are not historical facts, but reflect the current expectations of management of Filament regarding future results or events and are based on information currently available to them. Certain material factors and assumptions were applied in providing these forward-looking statements. The forward-looking statements discussed in this press release may include, but are not limited to, information concerning Filament’s and TrPR’s ability to conduct clinical trials; the results of the partnership; the nature, timing, and possible success of Filament’s leading drug candidates and the impact and accessibility of psychedelic treatments. Forward-looking statements regarding the Company are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of Filament to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Filament will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.

Posted on

Regulatory Approvals Place Filament Health at the Forefront of Natural Psychedelic Research and Manufacturing

Health Canada Dealer’s License to allow the possession, production, and delivery of all controlled natural psychedelic substances

Vancouver, British Columbia, July 29, 2021 –  Filament Health Corp. NEO:FH. (“Filament” or the “Company”), a global leader in natural psychedelic drug development, has been granted an amendment to its existing Health Canada Dealer’s License, amplifying the Company’s position at the forefront of natural psychedelic research and manufacturing.

Filament operates a state-of-the-art GMP facility currently manufacturing drug candidates naturally extracted from psychoactive mushrooms. The amendment to Filament’s Health Canada Dealer’s License allows the possession, production, research supply, export, import, and delivery for all remaining controlled natural psychedelic substances, including N,N-dimethyltryptamine, mescaline, and others. Filament will seek to create the first-ever natural pharmaceutical grade extracts of these substances and enter them into clinical trials to demonstrate their safety and efficacy.

“This license amendment significantly increases the scope of our work with natural psychedelics,” said Filament’s Director of Research, Ryan Moss. “By studying untapped psychedelics in a scientific setting, we believe we can unlock and standardize their healing power. This is a promising step forward in our mission to get safe, natural psychedelics into the hands of everyone who needs them, as soon as possible.”

The compounds covered by Filament’s license amendment have a long history of use in traditional medicine and recreational settings. The company plans to develop naturally derived, standardized preparations, and study their applications for therapeutic use to treat a range of health conditions.

“We are encouraged by this development, which we believe strengthens Filament’s position and opens up new revenue sources for us,” said Filament Chief Executive Officer Benjamin Lightburn. “The benefits of these valuable plants are well-documented; we will be among the first to purposefully explore their pharmaceutical applications.”

Filament will produce the psychedelic extracts in-house at its GMP-certified facility in Metro Vancouver, where it has also developed compounds which will be studied in the first ever FDA-approved natural-psilocybin clinical trials, beginning in Q3 2021.

 

ABOUT FILAMENT HEALTH

Filament is an exclusively-natural psychedelic drug discovery and extraction technology company. Its mission is to see safe, approved, natural psychedelics in the hands of everyone who needs them as soon as possible. Filament believes measurable and efficacious medicines will be a catalyst to addressing many of the world’s mental health problems and that natural psychedelics provide an optimal option for widespread adoption of these substances. Filament engages in natural extraction technology commercialization, utilizing its intellectual property portfolio, in-house GMP facility, and Health Canada Dealer’s License for all natural psychedelics. Filament is headquartered in Vancouver, British Columbia and trades on Canada’s NEO Exchange (NEO:FH).

Learn more at www.filament.health and get the latest updates via Filament’s Newsletter, and LinkedIn page.

 

MEDIA CONTACT

Anna Cordon, Director of Communications
778.245.9067
anna@filament.health

 

INVESTOR RELATIONS

ir@filament.health

 

FORWARD LOOKING INFORMATION

Certain statements and information contained herein may constitute “forward-looking statements”and “forward-looking information,” respectively, under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as, “expect”, “anticipate”, “continue”, “estimate”, “may”, “will”, “should”, “believe”, “intends”, “forecast”, “plans”, “guidance” and similar expressions are intended to identify forward-looking statements or information. The forward-looking statements are not historical facts, but reflect the current expectations of management of Filament regarding future results or events and are based on information currently available to them. Certain material factors and assumptions were applied in providing these forward-looking statements. The forward-looking statements discussed in this press release may include, but are not limited to, information concerning Filament’s and TrPR’s ability to conduct clinical trials; the results of the partnership; the nature, timing, and possible success of Filament’s leading drug candidates and the impact and accessibility of psychedelic treatments. Forward-looking statements regarding the Company are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of Filament to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Filament will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.